Format

Send to

Choose Destination
Am J Clin Oncol. 2011 Apr;34(2):179-87. doi: 10.1097/COC.0b013e3181d6b427.

Melanoma: from darkness to promise.

Author information

1
Medical Oncology Service, Hospital Marina Alta de Dénia, Alacant, Spain. joanmagasent@telefonica.net

Abstract

Metastatic melanoma is one of the most resistant tumors to standard chemotherapy approaches. The median overall survival of patients diagnosed with metastatic melanoma is lower than 9 months. Current approved treatments offer only marginal survival advantages. New immunotherapeutic targets have appeared recently trying to modulate the host immune response against the tumor. New targeted agents have changed the standard of care of other solid tumor types like breast cancer. Here, we discuss the new advances and achievements in the treatment of this highly resistant disease.

PMID:
20498590
DOI:
10.1097/COC.0b013e3181d6b427
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center